What is the fair value of Penumbra Inc (NYSE-PEN) stock?

The current fair value estimate for Penumbra Inc (NYSE-PEN) is $268.25. This implies an estimated downside of 15.5% versus the current market price.

Is Penumbra Inc (NYSE-PEN) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 15.5% versus the current market price.

What is the analyst price target for NYSE-PEN stock?

The available analyst price target for Penumbra Inc (NYSE-PEN) is $361.83. The analyst target implies estimated upside of 13.9%.

How is the financial health of Penumbra Inc?

The current financial health read for Penumbra Inc (NYSE-PEN) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Penumbra Inc's next earnings date?

The next earnings date currently listed for Penumbra Inc (NYSE-PEN) is November 4, 2026.

Does Penumbra Inc (NYSE-PEN) pay dividends?

The latest available data indicates no current dividend yield for Penumbra Inc (NYSE-PEN).

What is the P/E ratio for Penumbra Inc (NYSE-PEN)?

The current P/E ratio listed for Penumbra Inc (NYSE-PEN) is 77.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Penumbra Inc?

The current market capitalization listed for Penumbra Inc is 12.51 B.

What is the enterprise value of Penumbra Inc?

The current enterprise value listed for Penumbra Inc is 12.064 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Penumbra Inc?

The ticker symbol for Penumbra Inc is NYSE-PEN, and the stock is listed on NYSE.

Where is Penumbra Inc (NYSE-PEN) listed?

Penumbra Inc (NYSE-PEN) is listed on NYSE.

What is the debt-to-total-capital ratio for Penumbra Inc?

The current debt-to-total-capital ratio listed for Penumbra Inc is 1.7%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Penumbra Inc?

The free float listed for Penumbra Inc is 97.2%. Free float helps investors understand how much of the share base is available for public trading.

Penumbra Inc (PEN) Fair Value & Stock Analysis

Penumbra Inc (PEN)

Penumbra, Inc. is a healthcare company focused on medical device design, development, manufacturing, and commercialization in the United States and international markets. Its product portfolio includes systems for thrombectomy, such as the Indigo System, Lightning Flash, Lightning Bolt 7, CAT RX, and the Penumbra System, along with a range of access products and catheters sold under brands including Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25, MIDWAY, and PX SLIM. The company also develops neuro embolization products for aneurysms and other complex lesions, peripheral embolization platforms, and neurosurgical tools such as the Artemis Neuro Evacuation Device. Penumbra sells its products through direct sales teams and distributors. Founded in 2004, the company is based in Alameda, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NYSE-PEN	$268.25	-15.5% Downside	Fair	$361.83	13.9% Upside	Fair	Great	0.0%	November 4, 2026	77.9x	8.2x	8.3x	12.51 B	12.064 B	1.7%	97.2%	19.1	134.4%